Press Releases

Date Title
July 7, 2021
Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer
Experienced executive with a track-record of successful eye care product launches Appointment reflects Outlook Therapeutics’ dedication to transition to commercial-stage company ISELIN, N.J. , July 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.
June 14, 2021
Outlook Therapeutics Announces Inclusion in the Russell 2000® Index
ISELIN, N.J. , June 14, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that as part of the annual
June 8, 2021
Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
Topline readout of data from NORSE TWO targeted for calendar Q3 2021 New Biologics License Application (BLA) filing anticipated in calendar Q1 2022 ISELIN, N.J. , June 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to
May 27, 2021
Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010
Drs. Mark Humayun and Firas Rahhal , leading retinal specialists and Advisors to Outlook Therapeutics , stress clinical value of ONS-5010, if approved, over existing treatment options Registration clinical program and pre-commercialization planning for ONS-5010 remains ongoing with key catalysts
May 14, 2021
Outlook Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Corporate Update
Topline efficacy and safety data from pivotal Phase 3 NORSE TWO study on target to report in calendar Q3 2021 Recently reported topline data from the NORSE THREE open-label safety study reinforce positive safety profile of ONS-5010 seen in the earlier clinical experience trial (NORSE ONE) ISELIN,
May 12, 2021
Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021
Live video webcast with Outlook Therapeutics’ management team and key opinion leaders on Thursday, May 20th from 11:00 AM – 1:00 PM ET ISELIN, N.J. , May 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the
March 31, 2021
Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
Positive safety profile in NORSE THREE open-label safety study reinforces previously reported safety data for ONS-5010 / LYTENAVA™ , an investigational ophthalmic formulation of bevacizumab-vikg for the treatment of wet AMD Topline efficacy and safety data from pivotal Phase 3 NORSE TWO study on
March 4, 2021
Outlook Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
MONMOUTH JUNCTION, N.J. , March 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence
February 17, 2021
Outlook Therapeutics to Participate in Cantor Fitzgerald’s Virtual Panel Discussion: Eyeing Key Events and Programs in the Ophthalmology Space in 2021
MONMOUTH JUNCTION, N.J. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence
February 16, 2021
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2021 and Provides Corporate Update
Topline data from pivotal Phase 3 safety and efficacy study (NORSE TWO) on target to report in Q3 2021 Topline data from the open-label safety study (NORSE THREE) on target to report in Q2 2021 Recent funding significantly enhances financial position, extends cash runway through BLA filing and
Displaying 1 - 10 of 119